TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY

被引：0
|
作者：
Bell, J. [1 ]
Galaznik, A. [1 ]
Farrelly, E. [2 ]
Blazer, M. [2 ]
Shih, H-C. [2 ]
Raju, A. [2 ]
Ogbonnaya, A. [2 ]
Eaddy, M. [2 ]
Fram, R. [1 ]
Faller, D. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Xcenda, Palm Harbor, FL USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1196
引用
收藏
页码：491 / 492
页数：2
相关论文
共 50 条
  • [31] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre C.
    Sekeres, Mikkael A.
    Westermann, Jorg
    Xiao, Zhijian
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Ma, Fei
    Kiertsman, Flavia
    Stegert, Mario
    Hertle, Sabine
    Fenaux, Pierre
    Santini, Valeria
    BLOOD, 2020, 136
  • [32] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai Alexandrovich
    Giri, Smith
    Stahl, Maximilian
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Woodman, Richard C.
    Adesanya, Afoluso Ronnee
    Azarnia, Nozar
    Parris, Matthew
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [34] NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
    Kotsianidis, I.
    Hatzimichael, E.
    Pappa, V.
    Galanopoulos, A.
    Kourakli, A.
    Diamantopoulos, P.
    Papageorgiou, S.
    Liapis, K.
    Papadopoulos, V.
    Papoutselis, M.
    Bouchla, A.
    Georgoulis, V.
    Vassilakopoulos, T.
    Solomou, E.
    Dimou, M.
    Vassilopoulos, G.
    Vardi, A.
    Papaioannou, M.
    Pontikoglou, C.
    Anagnostopoulos, A.
    Panayiotidis, P.
    Kontopidou, F.
    Harchalakis, N.
    Adamopoulos, N.
    Ximeri, M.
    Zikos, P.
    Megalakaki, A.
    Repousis, P.
    Kotsopoulou, M.
    Dryllis, G.
    Tsoukanas, D.
    Kyrtsonis, M. -C.
    Poulakidas, E.
    Bouronikou, E.
    Delimpasis, S.
    Mparmparousi, D.
    Papadaki, H.
    Vyniou, N. A.
    Symeonidis, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [35] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [37] The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia
    Zeidan, Amer
    Esteve, Jordi
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre
    Westermann, Joerg
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Kiertsman, Flavia
    Stegert, Mario
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S188
  • [38] The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
    Zeidan, Amer M.
    Al Ali, Najla H.
    Kharfan-Dabaja, Mohamed A.
    Padron, Eric
    Zhang, Ling
    Epling-Burnette, Pearlie K.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [39] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    BLOOD, 2019, 134
  • [40] PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROMA PHASE II, OPEN-LABEL STUDY.
    Laille, E.
    Xiao, Z.
    Du, X.
    Dong, Q.
    Songer, S.
    Beach, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81
12345